Physician profile
Michael W Perry
NPI 1184010084
$13,869.52
in general payments reported to CMS, 2019-2025
10 companies · $3,291 in 2025
The $3,291 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $852 · 2020: $837 · 2021: $1,462 · 2022: $4,761 · 2023: $1,306 · 2024: $1,361 · 2025: $3,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,190 · Consulting Fee: $1,680 · Education: $87.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.40 |
| Consulting Fee | $1,680.00 |
| Education | $87.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $6,093.96 | 2019-2025 | Mako, Insignia, Actishield |
| Medical Device Business Services, INC. | $2,761.39 | 2019-2025 | Velys, Attune |
| Zimmer Biomet Holdings, INC. | $2,677.55 | 2021-2025 | Persona, Mymobility Platform, Arcos Revision Hip Instrumentation |
| Depuy Synthes Sales INC. | $1,616.30 | 2019-2025 | Na, Emphasys, Attune |
| Trice Medical, INC. | $180.64 | 2022 | |
| Ferring Pharmaceuticals INC. | $172.15 | 2023-2025 | Euflexxa |
| Smith+Nephew, INC. | $168.47 | 2020-2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Orthalign INC | $138.46 | 2022 | |
| Bioventus LLC | $37.48 | 2024-2025 | Durolane, Xcell |
| Leo Pharma INC. | $23.12 | 2025 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.